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Neural network training and validation rely on the availability of large high-quality datasets.
However, in many cases only incomplete datasets are available, particularly in health care appli-
cations, where each patient typically undergoes different clinical procedures or can drop out of a
study. Since the data to train the neural networks need to be complete, most studies discard the
incomplete datapoints, which reduces the size of the training data, or impute the missing features,
which can lead to artefacts. Alas, both approaches are inadequate when a large portion of the data
is missing. Here, we introduce GapNet, an alternative deep-learning training approach that can use
highly incomplete datasets. First, the dataset is split into subsets of samples containing all values
for a certain cluster of features. Then, these subsets are used to train individual neural networks.
Finally, this ensemble of neural networks is combined into a single neural network whose training is
fine-tuned using all complete datapoints. Using two highly incomplete real-world medical datasets,
we show that GapNet improves the identification of patients with underlying Alzheimer’s disease
pathology and of patients at risk of hospitalization due to Covid-19. By distilling the information
available in incomplete datasets without having to reduce their size or to impute missing values,
GapNet will permit to extract valuable information from a wide range of datasets, benefiting diverse
fields from medicine to engineering.
I. INTRODUCTION
Supervised machine-learning models, such as the neu-
ral networks employed in deep learning, require to be
trained and validated on large high-quality datasets [1].
In particular, these datasets need to be complete, i.e.,
each datapoint needs to have the values of all features,
in order for them to be employed in standard neural-
network training algorithms [2]. However, in many appli-
cations only incomplete datasets are available, i.e., each
datapoint has values only for some of the relevant fea-
tures [3]. For example, this often occurs in medical ap-
plications involving patient data, e.g., because various
patients might undergo different clinical and diagnostic
procedures at different times, with some patients even
dropping out from a study [3].
In order to deal with these missing data, there are two
standard approaches. The first and most commonly em-
ployed one is to exclude the datapoints that do not have
all relevant features [4]. This approach has the advantage
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of ensuring the integrity of the data employed in train-
ing and validation, but it has the drawback of reducing
the statistical power of the dataset [5] and, therefore, the
predictive ability of the resulting deep-learning models
[6]. Furthermore, data exclusion can introduce biases if
the data are not missing completely at random [7].
The second and more complex approach is to impute
the missing data. Various statistical imputation strate-
gies have been proposed. The simplest one is arguably
to substitute the missing values with their ensemble aver-
age [7]. More sophisticated imputation strategies obtain
better results employing, e.g., multilayer perceptrons, ex-
treme gradient boosting machines, and support vector
machines [8–10]. For example, Vivar et al. [11] improved
the classification of individuals in the datasets of the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) and
the Parkinson’s Progression Markers Initiative (PPMI)
by employing a multiple recurrent graph convolutional
network to impute the missing features (the brain vol-
umes obtained from magnetic resonance imaging (MRI)).
However, a major drawback of data imputation is that it
can amplify biases in the available data or even introduce
spurious correlations [4], especially when data are missing
in great numbers or not at random [12]. Because of their
drawbacks, both exclusion and imputation strategies can
only deal with a limited amount of missing data.
To address these limitations, here we introduce Gap-
Net, an alternative neural-network training approach
based on a hierarchical architecture that can make use
of highly incomplete datasets. GapNet takes advantage























tation of missing data. First, the dataset is split into
subsets containing all datapoints with a certain cluster
of features. Then, these subsets are used to train indi-
vidual neural networks. Finally, this ensemble of neural
networks is combined into a single neural network whose
training is fine-tuned using all complete datapoints. As
real-world test cases with highly incomplete datasets, we
show that GapNet improves the identification of patients
in the Alzheimer’s disease continuum in the ADNI cohort
and of patients at risk of hospitalization due to Covid-19
in the UK BioBank cohort. By distilling the information
available in large incomplete datasets without having to
reduce their size or to impute missing values, GapNet al-
lows extracting valuable information from a wider range
of datasets, being employable for many applications.
II. RESULTS
A. GapNet working principle
To demonstrate the GapNet working principle, we first
apply it on a simulated dataset, representing a two-class
classification problem with F continuous input features.
Specifically, we employ the simulated dataset Madelon
[13], where the datapoints are clustered around the ver-
tices of an F -dimensional hypercube and assigned to the
class of the closest vertex (see details in Methods, “Sim-
ulated dataset”). Figure 1a provides a schematic illus-
tration for the case F = 3. Here, we consider a system
with F = 40 features, so that
y = f(x1, . . . , x40), (1)
where y ∈ {0, 1} is the class assignment for each data-
point. As shown in Figure 1b, the dataset consists of
1000 samples, where only 100 samples have all the 40
features: samples 1 to 450 have only features x26 to x40;
samples 551 to 1000 have only features x1 to x25; while
samples 451 to 550 have all features.
To establish a benchmark, we first consider a vanilla
neural network approach, which is schematically shown
in Figure 1c. We employ a dense neural network hav-
ing an input layer with 40 nodes corresponding to the 40
features, two hidden layers with 80 nodes each (ReLU ac-
tivation), a dropout layer with a frequency of 0.5, and an
output layer with a single node (sigmoidal activation).
This vanilla neural network must be trained using the
complete samples. Thus, we split the available 100 com-
plete samples into a 80-sample training set and a 20-
sample testing set. We train the neural network for 2000
epochs using the Adam optimizer [15] with binary cross-
entropy loss.
The GapNet approach involves a two-stage training
process, as schematically presented in Figure 1d. In
training stage I (Figure 1d), the input feature space is
split into a set of non-overlapping clusters for which com-
plete samples are available. We then train a neural net-
work using each of these clusters to predict the desired
output. In the current example, we identify two clusters
of features, the first one corresponds to features 1 to 25
(dark green area in Figure 1b) and the second one to
features 26 to 40 (light green area), each with 550 sam-
ples. Then, we train two dense neural networks to predict
y using x1, . . . , x25 and x26, . . . , x40, respectively. Each
neural network consists of an input layer (with 25 and 15
nodes, respectively, corresponding to each cluster of fea-
tures), two hidden layers (with 50 and 30 nodes, respec-
tively, with ReLU activation), a dropout layer (frequency
0.5), and finally an output layer with a single node (sig-
moidal activation). We train these neural networks on
the available samples (retaining 20 complete samples for
testing, the same for both neural networks) for 2000
epochs (Adam optimizer [15], binary cross-entropy loss).
In training stage II (Figure 1d), the input and hid-
den layers of the first-stage neural networks are com-
bined into a single neural network, adding an output
node (sigmoidal activation). These new connections are
trained for 2000 epochs (Adam optimizer [15], binary
cross-entropy loss) using all available complete samples
(retaining for testing the same 20 samples used for testing
in training stage I).
In order to statistically compare the performance of
GapNet to the performance of the vanilla neural network,
we repeat the training and testing procedures 100 times
with resampling of the training and testing datasets.
We evaluate the performance using the receiver operator
characteristic (ROC) curve, which plots the true posi-
tive rate (TPR) versus the false positive rate (FPR) as
a function of the threshold. The area under the ROC
curve (AUC) is then 0.5 for a random estimator and ap-
proaches 1 as the estimator performance improves. In
Figure 1e, we show the ROC curve for GapNet (orange
line) and vanilla neural network (blue line), obtained as
the average over 100 repetitions, while the corresponding
variance is shown by the shaded areas. The GapNet ap-
proach (AUC 0.89± 0.11) outperforms the vanilla neural
network (AUC 0.68 ± 0.17). This difference is statisti-
cally significant with a p-value p < 0.0001 (z = 20.6),
tested using the Delong test [14]. In addition to the
AUC comparison, Table I shows the sensitivity, speci-
ficity, accuracy, and precision computed by setting the
threshold at 0.5. All the metrics are improved by using
GapNet, showing its ability to correctly identify the true
positive and true negative cases. Interestingly, the vari-
ability of the GapNet approach is smaller than that of the
vanilla neural network approach, indicating more consis-
tent training results. Figure 1f shows the histograms of
the AUC values for each independent run. The peak for
the GapNet is larger than that of the vanilla neural net-
work, indicating GapNet achieves a consistently better
performance, increasing the robustness of the classifica-
tion to the missing data.
Overall, these proof-of-principle results on simulated
data show the effectiveness and robustness of the GapNet
approach to fully exploit incomplete datasets. Thus, the









































Figure 1. GapNet improves the classification of simulated data. a Schematic representation of Madelon [13], an
artificial dataset used to test binary classification problems. The points in the dataset are clustered around the vertices of an
hypercube with dimensions corresponding to the number of features (F = 3 in the schematic) and attributed to 2 different
classes (corresponding to the pink and red circles in the schematic). b We simulate N = 1000 samples with F = 40 features
(x1, ..., x40). Colored areas represent the available data, while the white areas represent the missing data: Only 100 samples
(samples 451 to 550, highlighted by the thick black line) have all 40 features. c The baseline benchmark is provided by a vanilla
neural network trained and tested on the complete samples. d The GapNet approach: In training stage I, subsets containing
all samples with certain features are used to train individual neural networks. In training stage II, their outputs are combined
by an output node, whose connections are trained with all complete samples. e The receiver operator characteristic (ROC)
curve showing the true positive rate (TPR) versus the false positive rate (FPR) of the GapNet (orange, area under the curve
(AUC) 0.89± 0.11) is significantly better than that of the vanilla neural network (blue, AUC 0.68± 0.17). Average (lines) and
standard deviations (shaded areas) are obtained from 100 random splits of the training and testing datasets. The black dashed
line represents the ROC curve of a random classifier. To establish statistical significance, the classifiers are also compared using
the Delong test [14] resulting in a significant p-value < 0.0001 (z = 20.6). f Comparing the histograms of the AUC values for
each independent run of the GapNet (orange) and the vanilla neural network (blue), we observe that GapNet delivers better
results (larger AUC) in a more consistent way (smaller variance).
able data, without having to impute the missing data.
B. Identification of patients in the Alzheimer’s
disease continuum in the ADNI cohort
As a first real-world GapNet application, we consider
the identification of individuals with underlying amy-
loid pathology, which is one of the earliest pathologi-
cal changes occurring in Alzheimer’s disease (AD) [16–
19]. We use data from the ADNI cohort (see Methods,
“ADNI cohort”). In total, 869 individuals underwent
1465 neuroimaging visits including both baseline visits
and subsequent longitudinal follow-up visits for some in-
dividuals. In each visit, one or more of the following
three neuroimaging modalities were employed: structural
magnetic resonance (MRI), amyloid positron emission to-
mography (amyloid-PET), and fluorodeoxyglucose-PET
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Table I. Performance of GapNet and vanilla neural network. Comparison between the performance of GapNet and that
of the vanilla neural network in terms of sensitivity, specificity, accuracy, and precision for the different datasets corresponding
to simulated data (Figure 1), neuroimaging data from the ADNI cohort (Figure 2), and Covid-19 severity predictions from the
UK BioBank cohort (Figure 3). The numbers in bold represent the best results for each category. GapNet improves all the
metrics for all datasets.
(FDG-PET), which are normally used to assess gray
matter atrophy, amyloid deposition and glucose hy-
pometabolism in AD, respectively (Figure 2a). For MRI,
we include the mean thickness of the 68 cortical regions of
the Desikan atlas [20] and the volumes of 14 subcortical
gray matter regions of the Aseg atlas [21]. For amyloid-
PET, we include the mean amyloid standard uptake value
ratio (SUVR) values from the same brain regions in-
cluded in MRI. For FDG-PET, we include the SUVR
of 5 composite brain regions [22]. The final number of
features is 169, and the corresponding regions of inter-
est (ROIs) are listed in Supplementary Table S1. MRI
scans were acquired in 233 visits, amyloid-PET scans in
1045 visits, and FDG-PET scans in 1258. Only 120 visits
(corresponding to 118 individuals, of which 40 cognitively
normal subjects without amyloid pathology and 78 sub-
jects with amyloid pathology) resulted in the acquisition
of all three neuroimaging modalities (Figure 2b).
To apply the GapNet approach (Figure 2c), we iden-
tify three clusters of features corresponding to the three
imaging modalities. We split the data into a training set
and a testing set. We define the testing set from 20% of
the complete data (Ntest = 24). We use the rest of the
data for the training set (Ntrain = 1441 including the re-
maining 80% of the samples with complete data as well as
all the incomplete samples). A schematic of the GapNet
architecture is shown in Figure 2c. In training stage I,
these three clusters of features are used to train three in-
dependent neural networks (input layer with 5, 82 and 82
nodes, respectively; two hidden layers with 10, 164, and
164 nodes, respectively, with ReLu activation; dropout
layer with frequency 0.5; output layer with single neuron
and sigmoidal activation). We train the MRI network on
209 samples, the amyloid-PET network on 1021 samples,
and the FDG-PET network on 1234 samples (in all cases
for 2000 epochs with binary cross-entropy loss function
and Adam optimizer). These three networks are then
combined into a single neural network in training stage
II with a joint output node, and the new connections
are retrained on the 96 complete training samples (2000
epochs, binary cross-entropy loss function, Adam opti-
mizer).
The ROC curves in Figure 2d show that the classifica-
tion performance of the GapNet approach (orange, AUC
0.91± 0.09) is superior than that of the standard vanilla
neural network (blue, AUC 0.87± 0.11). The shaded ar-
eas represent the variation of these ROC curves over 100
random splits between the training and testing sets. This
difference is statistically significant (Delong test [14], p-
value p < 0.0001, z = 7.76). In addition to the AUC
comparison, Table I shows the sensitivity, specificity, ac-
curacy and precision computed by setting the prediction
threshold at 0.5. All the metrics are improved by using
GapNet, showing its ability to correctly identify the true
positive and true negative cases [23].
Figure 2e shows the box plots with the AUC values
obtained over the independent runs for the GapNet ap-
proach, the networks trained on each of the data clusters,
and the vanilla neural network. The GapNet approach
achieves the best performance, outperforming the vanilla
neural network as well as all networks trained on a sin-
gle data cluster. Interestingly, the amyloid-PET-trained
neural network also outperforms the vanilla neural net-
work approach, probably taking advantage of its larger
training set (1021 instead of 94 samples). Nevertheless,
both the MRI-trained and the FDG-PET trained neural
networks underperform the vanilla neural network, de-
spite having access to more (233 and 1258, respectively)
samples.
In Figure 2f, we mapped the feature importance for
the GapNet model by performing a permutation feature
analysis [24]. The results show that 16 out of the most
important 20 features are derived from the amyloid-PET
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Figure 2. GapNet improves the identification of patients on the Alzheimer’s disease continuum in the ADNI
cohort. a Neuroimaging modalities (structural magnetic resonance (MRI), amyloid positron emission tomography (amyloid-
PET), and fluorodeoxyglucose-PET (FDG-PET)) and corresponding brain regions of interest (ROIs). Mean values in each ROI
are extracted by a standard Freesurfer processing pipeline. b Schematic representation of the dataset. The dataset corresponds
to 1465 visits in each of which one or more neuroimaging modalities are employed. Only 120 visits resulted in the acquisition
of all three neuroimaging modalities (highlighted by the thick black line). c GapNet: First a neural network with two hidden
layers is trained using each cluster of features (i.e., the brain region data for each neuroimaging modality). Then, all these
neural networks are concatenated to return the final output. d Receiver operating characteristic (ROC) curve showing that
GapNet (orange, AUC 0.91± 0.09) outperforms the vanilla neural network (blue, AUC 0.87± 0.11). The solid lines represent
the averages over 100 independent runs and the shaded areas the corresponding standard deviations. The black dashed line
represents the ROC curve of a random classifier. The classifiers are also compared using the Delong test [14] resulting in a
significant p-value p < 0.0001 (z = 7.76). e Box plots of the AUC values over the independent runs showing that GapNet
outperforms the vanilla neural networks trained either on all individuals with all diagnostic modalities (“Vanilla”) or on only one
diagnostic modality (“Amyloid”, “MRI”, or “FDG”). The red mark represents the median, the black boxes are the interquartile
ranges, and the black horizontal lines are the whiskers. f Relevance heatmaps for the GapNet classification between cognitively
normal individuals and patients in the Alzheimer’s disease continuum. The color-coded areas represent the regions with high
classification importance. For amyloid-PET (upper panel), these regions include the left pericalcarine, right pars trianularis,
bilateral superior parietal lobule, right precuneus, right postcentral lobule, left medial orbitofrontal cortex, right precentral
lobule at the cortical level, as well as bilateral hippocampus and bilateral amygdala at the subcortical level. For MRI (lower
panel), the regions are mainly from the right hemisphere, including the caudal anterior cingulate and posterior cingulate at the
cortical level as well as the right caudate and left pallidum at the subcortical level.
MRI. For amyloid-PET, the features included occipital
(left pericalcarine gyrus), frontal (right pars triangularis,
right postcentral gryus, left medial orbitofrontal cortex,
right precentral gyrus), parietal (bilateral superior pari-
etal gyri, right precuneus), and subcortical areas (bilat-
eral hippocampus, bilateral amygdala). For MRI, the
most important features included cortical thickness in
limbic (right caudal anterior cingulate and right poste-
rior cingulate) as well as volumes in subcortical areas
(right caudate, left pallidum). Crucially, most of these
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features (or ROIs) have been reported to be impaired
in AD by previous studies assessing patients at different
disease stages. For amyloid-PET, the orbito-frontal and
precuneus ROIs have been often identified in the early
stages of amyloid pathology [25]; the subcortical ROIs
(amygdala and hippocampus) are in line with the Aβ42
accumulation regions that have been reported in amy-
loid pathology during the early AD stages; and the other
three cortical ROIs (pericalcarine, postcentral, and pre-
central) are consistent with the Aβ42 accumulation re-
gions showing high SUVRs during the late AD stages [25].
For MRI, both the hightlighted cortical ROIs (caudal an-
terior cingulate and posterior cingulate) and subcortical
ROIs (caudate and pallidum) have also been reported in
previous studies on informative regions across different
stages of the AD continuum [26–31].
C. Prediction of Covid-19 hospitalization in the
UK BioBank cohort
As a second example of a real-world case application,
we consider an incomplete dataset to predict hospitaliza-
tion due to Covid-19. The dataset is based on the UK
BioBank cohort, which contains information concerning
Covid-19 test results, hospitalizations, and clinical exam-
inations (see details in Methods, “UK BioBank cohort”).
The aim of this analysis is to discriminate patients at
high risk of hospitalization due to severe Covid-19 symp-
toms from those at low risk of hospitalization, based on
their previous medical records.
The cohort includes 3926 individuals and 34 different
features with a varying number of records per feature,
ranging from 1123 to 3875 values. The parameters in-
clude sex, age and easily accessible testing information,
such as red blood and white blood cell counts (see Supple-
mentary Table S2 for the full list of features). The miss-
ing data are irregularly distributed across the dataset, so
we gather the attributes into 7 different clusters based
on the overlap between the features in order to mini-
mize the amount of information loss. Figure 3a shows
the clusters labeled from A to G and the attributes in-
cluded in each cluster. Figure 3b shows the input data
color-coded based on the different clusters, from cluster
A in yellow to cluster G in dark green. The colored areas
represent the data, while the missing values are shown as
white patches. Discarding all patients with incomplete
records leads to a reduced cohort of only 501 subjects, as
indicated by the black rectangle in Figure 3b.
The schematic representation of the GapNet approach
is provided in Figure 3c. We split the data into training
and testing sets. The testing set includes about 20%
(Ntest = 100) of the complete samples, while the training
set includes the remaining complete data (401 samples)
and all the incomplete data (Ntrain = 3826).
In training stage I, the seven clusters of features are
used to train seven independent neural networks with in-
put layer of 5 nodes, except for cluster A (with 4 nodes).
Each of these neural networks has 2 hidden layers with 10
nodes each (ReLu activation) and a dropout layer (fre-
quency 0.2). The output layer consist of a single neuron
(sigmoidal activation). We train the neural networks on
each cluster of inputs for 500 epochs using the binary
cross-entropy loss function and Adam optimizer. These
seven networks are then combined into a single neural
network in training stage II with a joint output node,
and the new connections are retrained on the complete
samples (500 epochs, binary cross-entropy loss function,
Adam optimizer).
Figure 3d shows that the ROC curve for the GapNet
approach (orange, AUC 0.69± 0.07) is significantly bet-
ter that that of the vanilla neural network (blue, AUC
0.60 ± 0.07) as demonstrated by the Delong test [14]
(p < 0.0001, z = 11.8). The solid lines are the aver-
age ROC curves over 100 repetitions of random split-
ting between the training and testing sets. Table I shows
that the sensitivity, specificity, accuracy, and precision
computed by setting the predictions’ threshold at 0.5 are
much improved by the GapNet approach.
Finally, we compare the performance of each cluster
to GapNet and the vanilla neural network in Figure 3e.
The results are sorted in descending order of median AUC
values. It is interesting to note that the GapNet results
are better than those of the best cluster, demonstrating
that combining the information in the clustered network
improves the classification task. Moreover, the shift in
the median between the GapNet and the subsequent best
cluster is larger than the average distance between single
clusters, showing a solid improvement in the predictions.
Figure 3e shows also that the training on some specific
features (included in clusters A and E) results in a better
predictor than using all 34 features while discarding the
missing data. A possible explanation is that the vanilla
neural network is trained on a smaller dataset (including
only the records from 501 patients), while the singular
clusters have a larger size (3875 and 1992 subjects for
clusters A and E, respectively).
III. DISCUSSION
The need to handle incomplete datasets is ubiquitous
in all fields dealing with empirical data, such as medicine
and engineering. While several imputation techniques
have been developed, they always rely on (explicit or im-
plicit) assumptions on the frequency and distribution of
missing values, and often incur the risk of introducing
biases. Here, we have proposed an alternative approach
that can be employed also when the missing data are very
frequent and not missing at random. We have called this
approach GapNet. In the GapNet approach, the neural
network undergoes two training stages, first training an
ensemble of neural networks, each on a data subset with
a complete cluster of features, and then combining these
into a single estimator that is fine-tuned on the available














Figure 3. GapNet improves the identification of patients at risk of hospitalization due to Covid-19 in the
UK BioBank cohort. a Seven clusters of features employed to predict hospitalization due to Covid-19 (sizes A → 3875,
B → 3713, C → 3622, D → 3109, E → 1992, F → 1123, and G → 1536). b The dataset comprises 3926 subjects and
34 features with colors representing the different clusters from A (yellow) to G (dark green). The white areas represent the
missing data. The 501 subjects with all features are delimited by black lines. c Network architecture employed for the GapNet
approach. Neural networks with two hidden layers are trained for each cluster and then concatenated to obtain a single output.
d Receiver operating characteristic (ROC) curve showing that GapNet (orange, AUC 0.69 ± 0.07) outperforms the vanilla
neural network (blue, AUC 0.60±0.07). The solid lines represent the averages over 100 independent runs and the shaded areas
the corresponding standard deviations. The black dashed line represents the ROC curve of a random classifier. The classifiers
are also compared using the Delong test [14] resulting in a significant p-value p < 0.0001 (z = 11.8). e Box plots showing the
statistics of the AUC over the independent runs. The red vertical lines mark the median value for each boxplot, the red dots
are the fliers, the black boxes are the interquartile ranges, and the black horizontal lines are the whiskers. The performance of
GapNet is better than that of the vanilla neural network. Furthermore, the results are compared with the training of neural
networks on the single clusters and the plot shows them in descending order of medians (see the Supplementary Table S2 for
the complete list of features and the extended names). The GapNet approach features the best outcome. Interestingly, the
features in clusters A and E alone result in better classifiers than the vanilla neural network.
the results for complete data when compared both with
a simple vanilla neural network approach trained only on
complete data and with the single-cluster-trained neural
networks. We have demonstrated the superior predic-
tive ability of the GapNet approach on three examples,
one corresponding to simulated data as a proof of prin-
ciple, and the other two on real-word medical datasets
of Alzheimer’s disease and Covid-19 patients. These
findings suggest that the improved predictions obtained
by the GapNet approach are potentially generalizable to
other datasets.
The major goal for the classification in the AD con-
tinuum is to establish a biomarker-based deep-learning
model. In this respect, the GapNet approach outper-
8
forms the vanilla neural network, delivering robust results
and detecting complex relationships when combining dif-
ferent imaging modalities. Noteworthy, the feature im-
portance analysis shows that the important brain regions
for the GapNet approach are in line with the brain areas
affected in AD reported by previous studies. Specifically,
the most predictive features are mainly derived from the
amyloid-PET modality, including parietal and frontal re-
gions, which are typical sites of amyloid accumulation in
AD [32]. These key findings on AD-related brain changes
suggest that the GapNet estimator is capable of produc-
ing robust predictions for early and accurate AD diagno-
sis.
A hot topic in COVID-19 research is to understand
the effect of other comorbid diseases and conditions on
the risk of developing severe Covid-19 symptoms [33–39].
This type of studies can help understanding, for instance,
which individual’s characteristics are associated with a
higher risk of hospitalization, and who should be con-
stantly monitored or prioritized in the vaccination pro-
cess [40–42]. However, when analyzing patient data, the
choice between discarding the incomplete values or im-
puting them, and the imputation technique employed [43]
can lead to different results [44–46] depending also on the
size of the cohort and the handling of missing data. Here,
we provide a simple example to predict severe Covid-19
outcomes, with the aim of pointing out the advantages of
using GapNet in this context: exploiting the incomplete
values and avoiding biases or alterations of the original
dataset. In the presented results, the incidence of the
different features is consistent with previous findings in
the literature. The most relevant clusters, in fact, include
features such as age, systolic and diastolic blood pressure
and serum creatinine levels (see details in Supplementary
Note A, “Feature importance analysis for Covid-19 sever-
ity”), connected with known Covid-19 high-risk comor-
bidities [37, 47, 48].
IV. CONCLUSION
In conclusion, we have proposed GapNet, a concep-
tually effective model of neural network architectures, to
produce more robust predictions in datasets with missing
values, which have become increasingly common in re-
search. We have shown how GapNet can detect complex
nonlinear relationships between all the variables and is
capable of learning and inferring from medical data with
incomplete features. We have verified the effectiveness of
GapNet in two real-world prominent datasets, the identi-
fication of patients in the Alzheimer’s disease continuum
in the ADNI cohort, and the prediction of patients at risk
of hospitalization due to Covid-19 in the UK BioBank
cohort. We believe that GapNet is a preliminary step
towards generic, scalable architectures that can investi-
gate many real-world medical problems, or even tasks
from many domains, holding great potential for several
future applications. One of the next steps will be to ap-
ply GapNet to more complex kinds of neural network
architectures, such as recurrent and convolutional neural
networks, as well as to apply it to more complex input
data, such as time sequences and images.
V. METHODS
A. Simulated dataset
To verify the working principle of GapNet, we use
a simulated dataset adapted from Madelon [13] imple-
mented with scikit-learn [49] (Figure 1a). We simulate a
binary-classification dataset including 1000 samples with
F = 40 features (x1, . . . , x40). Of these features, 25 are
informative features (x1, x3, x4, x5, x8, x10, x11, x13,
x14, x15, x18, x20, x22, x25, x26, x27, x28, x29, x31, x33,
x34, x35, x36, x39, x40), 10 are linear combinations of the
informative features (x2, x6, x7, x9, x12, x17, x19, x24,
x30, x37), and 5 are uncorrelated random noise without
information (x16, x21, x23, x32, x38). We introduce miss-
ingness in the dataset by removing the values of features
x1 to x25 from samples 1 to 450 and the values of fea-
tures x25 to x40 for samples 551 to 1000, so that only 100
samples (samples 451 to 550) are complete (Figure 1b).
B. ADNI cohort
The data used for this analysis were obtained from
the ADNI database (adni.loni.usc.edu). The ADNI
was launched in 2003 as a public–private partnership, led
by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial
magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clin-
ical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment
(MCI) and early Alzheimer’s disease (AD). The individ-
uals included in the current study were recruited as part
of ADNI-GO and ADNI-2. This study was approved by
the Institutional Review Boards of all participating in-
stitutions. Informed written consent was obtained from
all participants at each site. For up-to-date information,
see adni.loni.usc.edu.
Amyloid pathology has been identified using a cut-off
of > 976.6 pg/ml on cerebrospinal fluid (CSF) levels of
Aβ42, following previously established procedures [50].
Subjects who are cognitively normal and have high CSF
Aβ42 values are used as a healthy reference group, while
subjects who are cognitively normal, have mild cognitive
impairment, or AD dementia with low CSF Aβ42 values
are included in the group with high risk of having AD
(the AD continuum group).
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C. UK Biobank cohort
The dataset employed in the prediction of Covid-
19 hospitalization is based on the general practition-
ers’ records provided by the UK BioBank dedicated to
Covid-related research [51]. We build the labels using
the COVID-19 test result records and the hospital inpa-
tient register data. The labels are assigned ‘0’ for patients
positive to Covid-19 who do not appear in the hospital
records, and ‘1’ for patients hospitalized due to Covid-19
and identified by the ICD-10 diagnostic code U07.1 [52].
The input values come from merging the primary care
data from the two largest providers, TPP [53] and EMIS
[54]. The data are cleaned to obtain the dataset: we se-
lect the patients positive to Covid-19, we filter only the
medical coding systems SNOMED CT [55] and CTV3
[56], and we include records in the five years interval 1
January 2015 to 1 January 2020 (antecedent to the first
reported case in the dataset). The selected values include
many standard medical examinations, such as pressure
measurements, body weight, and blood tests. At this
point, we cut the less common codes to obtain a dataset
of 501 subjects with complete features and we undersam-
ple the more represented category (the non-hospitalized
subjects are nearly five times larger) to obtain a balanced
dataset. The final number of attributes incorporated is
34, listed in Table ?? together with their corresponding
Read Code.
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